CLS-014
Pancreatic Cancer
Pre-clinicalLead candidate
Key Facts
About CLS Therapeutics
CLS Therapeutics is translating the emerging biology of circulating nucleic acids into transformative gene therapies for cancer. Founded by scientists and biotech entrepreneurs, the company is advancing its lead program, CLS-014, a novel AAV vector encoding a hyperactive DNase I enzyme, to clean pathogenic cfDNA from patients' blood. With a team of experts in cfDNA research, gene therapy, and oncology, CLS is focused on treating gastrointestinal cancers and has engaged in strategic collaborations to advance its platform.
View full company profileTherapeutic Areas
Other Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ARV-806 | Arvinas | Phase 1 |
| CPI-613 (devimistat) + Hydroxychloroquine | Rafael Holdings | Phase 1/2 |
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| SON-1210 | Sonnet BioTherapeutics | Phase 1/2a |